RGFP966
RGFP966 性质
| 沸点 | 630.4±55.0 °C(Predicted) |
|---|---|
| 密度 | 1.19±0.1 g/cm3(Predicted) |
| 储存条件 | -20°C |
| 溶解度 | 可溶于 DMSO（高达 20 mg/ml） |
| 形态 | 固体 |
| 酸度系数(pKa) | 11.58±0.70(Predicted) |
| 颜色 | 米白色 |
| 稳定性 | 可在-20°C下的DMSO溶液保存长达1个月。 |
| InChI | InChI=1S/C21H19FN4O/c22-18-9-10-20(19(23)13-18)25-21(27)11-8-17-14-24-26(15-17)12-4-7-16-5-2-1-3-6-16/h1-11,13-15H,12,23H2,(H,25,27)/b7-4,11-8+ |
| InChIKey | BLVQHYHDYFTPDV-WPGSJKDTSA-N |
| SMILES | C(NC1=CC=C(F)C=C1N)(=O)/C=C/C1=CN(CC=CC2=CC=CC=C2)N=C1 |
RGFP966 用途与合成方法
|
HDAC3 80 nM (IC 50 ) |
RGFP966 potently and selectively inhibits HDAC 3 with IC 50 of 0.21 μM in RAW 264.7 macrophages, while HDACs 1 (IC 50 =5.6 μM), 2 (9.7 μM) and 8 (>100 μM), indicating a good level of selectivity for HDAC 3. The mRNA levels of HDACs 1, 2 and 3 are not significantly affected by RGFP966 in RAW 264.7 macrophages, whereas the HDAC 1 and HDAC 2 protein levels are slightly, though significantly, reduced upon RGFP966 treatment. Moreover, RGFP966 significantly reduced the transcriptional activity of NF-κB p65, whereas NF-κB p65 acetylation and localization remain unaltered.
RGFP966 (10 and 25 mg/kg) treatment significantly improves body weight, rotarod performance and several measures of motor function in the open field locomoter test. RGFP966 at a 10 mg/kg dose penetrates the blood-brain barrier into rat auditory cortex with typical pharmacokinetics, which together establish feasibility for the modulation of A1 plasticity due to action in the auditory cortex.
RGFP966 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-09-15 | HY-13909 | RGFP966 | 1357389-11-7 | 1 mg | 360 |
| 2026-09-15 | HY-13909 | RGFP966 | 1357389-11-7 | 5mg | 900 |
